Regeneron Pharmaceuticals REGN Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $14.92B+5.9% | $14.34B+1.0% | $14.25B+2.9% | $14.21B+5.4% | $14.09B+7.5% | ||
| —— | —— | —— | —— | —— | ||
| $6.07B+16.4% | $5.85B+14.0% | $5.64B+15.1% | $5.43B+15.6% | $5.21B+13.6% | ||
| $2.71B-6.3% | $2.7B-8.6% | $2.72B-6.3% | $2.77B-1.8% | $2.9B+6.6% | ||
| $11.29B+10.1% | $10.77B+5.4% | $10.56B+6.9% | $10.37B+8.2% | $10.25B+10.9% | ||
| $3.63B-5.3% | $3.58B-10.3% | $3.69B-7.2% | $3.84B-1.6% | $3.83B-0.5% | ||
| 24.3%-2.9pp | 24.9%-3.2pp | 25.9%-2.8pp | 27%-1.9pp | 27.2%-2.2pp | ||
| $48M+0.4% | $43.8M-20.7% | $42.1M-33.2% | $36.6M-45.4% | $47.8M-32.8% | ||
| $1.53B+28.9% | $1.65B+101% | $1.49B+49.5% | $1.07B+56.2% | $1.19B+523% | ||
| $5.16B+3.5% | $5.23B+9.4% | $5.15B+3.5% | $4.87B+6.3% | $4.98B+23.3% | ||
| $733.5M+51.3% | $725.8M+97.6% | $567.1M+73.5% | $416.2M+50.0% | $484.9M+147% | ||
| $4.42B-1.7% | $4.5B+2.1% | $4.58B-1.6% | $4.46B+3.2% | $4.5B+16.6% | ||
| 29.6%-2.3pp | 31.4%+0.3pp | 32.1%-1.5pp | 31.4%-0.7pp | 31.9%+2.5pp | ||
| $41.05+4.4% | $41.57+8.5% | $41.81+3.4% | $39.73+5.2% | $39.33+16.2% | ||
| $4.17B-3.6% | $4.12B-7.9% | $4.21B-5.2% | $4.35B-0.2% | $4.33B+0.9% | ||
| 27.9%-2.8pp | 28.7%-2.8pp | 29.6%-2.5pp | 30.6%-1.7pp | 30.7%-2.0pp | ||
| $3.63B-5.3% | $3.58B-10.3% | $3.69B-7.2% | $3.84B-1.6% | $3.83B-0.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Regeneron Pharmaceuticals's revenue?
- Regeneron Pharmaceuticals (REGN) generated $14.9B in revenue over the trailing twelve months, up 5.9% year over year.
- Is Regeneron Pharmaceuticals profitable?
- Regeneron Pharmaceuticals reported $4.4B in net income over the trailing twelve months, a 29.6% net margin.
- What are Regeneron Pharmaceuticals's profit margins?
- Gross margin is 93.9% and operating margin is 24.3%, with a 29.6% net margin.
- What is Regeneron Pharmaceuticals's earnings per share?
- Regeneron Pharmaceuticals's diluted EPS over the trailing twelve months is $41.05.
- Where does Regeneron Pharmaceuticals's income statement data come from?
- Every line is extracted from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
